GlaxoSmithKline receives EU authorisation for a new therapeutic indication for Tyverb® (lapatinib)On, GlaxoSmithKline

Release Date: 2010-06-23

GlaxoSmithKline (GSK) confirmed today that the European Commission (EC) has granted a variation to the conditional marketing authorisation for Tyverb® (lapatinib) in the European Union for a new therapeutic indication. Tyverb, in combination with an aromatase inhibitor, is indicated for the treatment of post-menopausal women with hormone receptor-positive, HER2 (ErbB2) over-expressing metastatic breast cancer and for whom chemotherapy is currently not intended. The patients in the registration study were not previously treated with trastuzumab or an aromatase inhibitor.

GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com
Type: NORMAL
Company: GlaxoSmithKline
Country: 英国
 
This website requires Flash Player 9 or later. If you can not view this site you probably need to update your system with this plug-in for your browser.